Targeting Rare Tumor Changes in Cancer Patients
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Recruiting
Observational Study
Cancer
Malignancies Multiple
Malignant Solid Tumor
Cancer, Therapy-Related
Molecular Sequence Variation
Genetic Alteration
Gene Fusion
Receptor Tyrosine Kinase Gene Mutation
RTK Family Gene Mutation
Ras (Kras or Nras) Gene Mutation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 5,500 (estimated)
- Sponsor
- University Health Network, Toronto · Other
Who this trial is looking for
This trial is looking for Canadian cancer patients with rare changes in their tumors. Participants will help researchers learn how these changes affect treatment and outcomes.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old when diagnosed with cancer.
- I have been diagnosed with malignant tumors.
- Molecular testing has found rare changes in my tumors.
- I have reports to confirm my molecular changes.
- I am a Canadian resident receiving or planning to receive cancer care in Canada.
You may not be able to join if
- I refused to participate in this study before I died.
- I cannot provide informed consent.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients ≥ 18 years at cancer diagnosis
* Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
* Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from…
Contacts